- Home
- AVR vs FULC Comparison
AVR vs FULC Comparison
Compare AVR & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVR
- FULC
- Stock Information
- Founded
- AVR 1999
- FULC 2015
- Country
- AVR Australia
- FULC United States
- Employees
- AVR N/A
- FULC N/A
- Industry
- AVR
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- AVR
- FULC Health Care
- Exchange
- AVR NYSE
- FULC Nasdaq
- Market Cap
- AVR 215.6M
- FULC 210.9M
- IPO Year
- AVR 2024
- FULC 2019
- Fundamental
- Price
- AVR $8.25
- FULC $3.85
- Analyst Decision
- AVR Strong Buy
- FULC Hold
- Analyst Count
- AVR 4
- FULC 9
- Target Price
- AVR $16.50
- FULC $7.63
- AVG Volume (30 Days)
- AVR 109.9K
- FULC 368.1K
- Earning Date
- AVR 01-01-0001
- FULC 02-25-2025
- Dividend Yield
- AVR N/A
- FULC N/A
- EPS Growth
- AVR N/A
- FULC N/A
- EPS
- AVR N/A
- FULC N/A
- Revenue
- AVR $2,826,588.00
- FULC $80,871,000.00
- Revenue This Year
- AVR N/A
- FULC $2,823.78
- Revenue Next Year
- AVR $25.66
- FULC N/A
- P/E Ratio
- AVR N/A
- FULC N/A
- Revenue Growth
- AVR N/A
- FULC 2987.86
- 52 Week Low
- AVR $5.10
- FULC $2.86
- 52 Week High
- AVR $8.79
- FULC $13.70
- Technical
- Relative Strength Index (RSI)
- AVR N/A
- FULC 47.75
- Support Level
- AVR N/A
- FULC $3.64
- Resistance Level
- AVR N/A
- FULC $3.94
- Average True Range (ATR)
- AVR 0.00
- FULC 0.18
- MACD
- AVR 0.00
- FULC 0.02
- Stochastic Oscillator
- AVR 0.00
- FULC 84.21
About AVR ANTERIS TECHNOLOGIES GLOBAL CORP
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.